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Abstract
Immune system activation and dysfunction characterize 
the early phase of reperfusion after a myocardial 
infarction (MI). Despite initially neglected, adaptive 
immunity has been recently showed to play an important 
role in this setting. In fact, the immune system can 
recognize sequestered antigens released by the necrotic 
tissue, initiating a deleterious autoimmune vicious circle 
leading to worse outcome. In their recent work, Angelini 
et al  shed the light on a new feature of post-MI which 
involves two “old players” of post-ischemic myocardial 
injury: CD31 and matrix metalloproteinase (MMP)-9. 
Specifically, the authors showed that an enhancement of 
MMP-9 release could determine the cleavage of inhibitory 
CD31 from CD4+ T-cells surface in patients with Acute 
Coronary Syndromes (ACS). These findings open the 
room for new studies investigating the role of MMP9 in 
other pathological processes associated with a reduction 
of CD31 functionality, such as plaque instability and 
rupture. Of interest, in the case of a causative role for 
CD31 shedding in ACS would be confirmed, there might 
be a potential role for the administration of CD31 protein 
or analogue compounds to blunt post-ischemic cardiac 
inflammation and improve ACS outcome. 
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Core tip: CD31 and matrix metalloproteinases (MMP)-9 
are known mediators that are upregulated during 
reperfusion after cardiac ischemia. By inhibiting T-cell 
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receptor-dependent lymphocyte activation, the functional 
CD31 could reduce post-ischemic inflammatory res-
ponse; while MMP-9 is deeply involved in inflammatory 
cell recruitment and myocardial remodeling. A recent 
paper published in European Heart Journal linked these 
mediators by showing CD31 cleavage to be MMP-9 
dependent in patients with acute coronary syndromes 
(ACS). Whether this process is causative of ACS or rather 
its effect still needs to be clarified. 
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INTRODUCTION
Acute Coronary Syndromes (ACS)-including unstable 
angina and myocardial infarction (MI) are the most 
detrimental atherosclerosis-related complications being the 
leading causes of mortality worldwide and a considerable 
source of morbidity[1]. Although outstanding leap forwards 
of primary and secondary prevention measures, the 
issue of the residual risk for ischemic complication is still 
unsolved[2]. Also, it is now well-recognized that after a 
prompt reperfusion, as it is the case of vast majority of 
patients suffering from MI, the ischemic hearts need to 
face an additional damage directly induced by the re-
establishment of blood flow itself[3]. The role of innate 
immunity in the determination of both residual risk 
and ischemia/reperfusion injury has been studied from 
decades and is now better established[4-6]. The adaptive 
immune system (i.e., T-cells and B-cells) have only 
recently come into focus. Indeed, lymphocytes’ ability to 
react only against specific non-self-antigens, as opposed 
to the reactivity against non-specific danger signal showed 
by innate immunity, excluded these mediators from 
the list of “guilty” parties for a long time. Only recently, 
the recognition of a role for the release of sequestered 
antigens from the necrotic tissue in the progressive 
diversification of autoreactive lymphocytes (i.e., epitope 
spreading) shed the light on the potential involvement 
of adaptive auto-reactivity in the determination of post-
MI outcome[7]. After an ACS, the necrotic heart tissue 
releases several danger-associated molecular patterns 
(DAMPs) together with cardiac intracellular proteins[8,9]. In 
this highly inflamed micro-environment, cardiac antigens 
can be recognized by autoreactive lymphocyte clones and 
trigger autoimmunity processes. Afterward, the same 
immune-mediated tissue injury supplies the amount of 
autoantigens necessary to maintain the auto-reactivity 
thus sustaining the dysfunctional immune cardiac 
process[9]. This editorial refers to the outstanding research 
article entitled “matrix metalloproteinases-9 might affect 
adaptive immunity in non-ST segment elevation ACS 
by increasing CD31 cleavage on CD4+ cells”, recently 
published by Angelini et al[10] in European Heart Journal.
T-CELLS AND ACS
Although several studies have implicated T-cells in the 
pathophysiology of ACS, the knowledge about their 
specific role is still elusive. Considering the heterogeneity 
of T-cell subsets and the quickly evolving local and 
systemic environment after ACS, a tight regulation of 
rapidly changing T-cell phenotypes with regulator or 
effector functions is likely[11]. Experimental evidence 
highlights infiltrating T-cells as effector lymphocytes 
which have been antigen-restricted and primed in the 
heart-draining lymph nodes. Of interest, after ACS, 
particular subsets of pro-inflammatory CD28- CD4+ 
and Th17 lymphocytes are released in the blood stream 
and produce large amounts of interferon-γ and IL-17: 
Detrimental cytokines with known ability to increase 
cardiomyocyte death, fibroblast proliferation and pro-
fibrotic gene expression[12-14]. Not only detrimental 
T-cells with effector functions are increased after ACS 
but they also display dysfunctional features. Indeed, 
they overexpress CD40 ligand in this way being 
more easily activated by antigen presenting cells[15]. 
Furthermore, a direct cytotoxic effect of infiltrating 
autoreactive CD8+ T-lymphocytes with specificity 
towards cardiac myosin has been described[16]. To further 
potentiate the detrimental role of T lymphocytes in the 
setting of MI, the raise of pro-inflammatory lymphocyte 
subsets is accompanied by a reciprocal reduction in 
CD4+CD25+Foxp3+ regulatory T-lymphocytes with a 
beneficial cardiac protective role[17].
MMP-9 AND CD31: A DANGEROUS 
ASSOCIATION
Post-transcriptional CD31 modifications showed capa-
city to affect normal T-lymphocyte function. Indeed, 
CD31 (also known as platelet endothelial cell adhesion 
molecule-1) was shown to regulate T lymphocyte activity 
through the inhibition of T cell receptor (TCR) signalling[18]. 
Of interest, CD31 extracellular domain is shed from the 
lymphocyte surface during ACS and this contributes 
to the over activation of adaptive immunity[19]. In their 
recent article, Angelini et al[10] added one more piece to 
this puzzle by showing matrix metalloproteinase (MMP)-9 
to be involved in CD31 cleavage in lymphocytes from 
ACS patients. Firstly, they confirm CD31 shedding to be 
a specific feature of lymphocytes in ACS, as compared 
to samples from healthy subjects but also patients with 
stable angina (SA). Then, the authors demonstrated in 
vitro that down-regulation of the functional CD31 domain 
in ACS is associated with TCR activation and is led by 
post-transcriptional mechanisms since post-stimulation 
levels of CD31 mRNA were similar in ACS and SA cells. 
Finally, after observing CD31 to be a possible substrate 
for MMP-9 by using an dedicated software predicting 
novel substrates and their cleavage sites, the auth-
124 October 26, 2018|Volume 10|Issue 10|WJC|www.wjgnet.com
Liberale L et al . T-cells in myocardial infarction
ors show lymphocytes from ACS patients to produce 
higher enzyme levels after stimulation and CD31 active 
domain to be preserved by MMP-9 inhibition. Based on 
these results, the authors propose a new sequence of 
events that might characterize ACS onset in which the 
increased release of MMP-9 causes CD31 cleavage, thus 
affecting TCR-dependent T-cell activation and causing 
T-cell hyperactivity[10]. 
PERSPECTIVES
Angelini et al[10] added knowledge to the field of dys-
functional adaptive immunity in ACS. At the same 
time, they raise new appealing questions. In particular, 
CD31 is known to mediate also endothelial-endothelial 
interactions, thus allowing the constitution of the con-
tinuous and protective intimal cell monolayer[20]. Now, 
further investigations are advisable to assess whether 
the inflammation-induced overproduction of MMP-9[21] 
could reduce these interactions and potentially contribute 
to endothelial erosion and plaque instability. Under 
this point of view, CD31 was previously described to 
target macrophage activation, as well as cytokine and 
chemokine release within atherosclerotic plaques and 
aneurysmal peri-aorta[22]. Also, it would be of interest 
to show CD31 modifications in lymphocytes to take act 
before ACS onset. In general, this is a very common 
weakness of studies focused on cellular phenotype 
during ACS due to the requirement of intact cells for 
fluorescent-activated sorting which does not allow 
sample storage before the dosage. Animal studies could 
help in assessing this causal connection.
Given the fact that CD31 protein or analog molecules 
are already available[23], answering these questions could 
point out CD31 replacement as a potential therapeutic 
approach to blunt inflammation and modulate tissue 
damage in acute cardiovascular diseases (such as MI and 
stroke) that are characterized by an impaired adaptive 
immunity. 
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